Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Postmenopausal osteoporosis: pathophysiology and prevention].

M Birkhäuser1

  • 1Abteilung für gynäkologische Endokrinologie, Universitäts-Frauenklinik Bern.

Schweizerische Rundschau Fur Medizin Praxis = Revue Suisse De Medecine Praxis
|April 16, 1991
PubMed
Summary

Hormone replacement therapy effectively prevents postmenopausal osteoporosis in high-risk women. Dosing guidelines exist for estrogen-progestin therapy, with other indications also supporting its use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2019
Same author

Quality of life in climacteric women.

Climacteric : the journal of the International Menopause Society·2017
Same author

Ultra-low dose - new approaches in menopausal hormone therapy.

Climacteric : the journal of the International Menopause Society·2014
Same author

Recommendations for raloxifene use in daily clinical practice in the Swiss setting.

European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society·2012
Same author

[Complications of hormonal contraception. 38th Congress of the "Zurich Discussion Group", April 2007].

Gynakologisch-geburtshilfliche Rundschau·2009
Same author

[Complications of hormonal contraception with estrogen and gestagens in the climacteric and in the postmenopausal period. 39th Congress of the "Zurich Discussion Group", October 2007].

Gynakologisch-geburtshilfliche Rundschau·2009

Area of Science:

  • Endocrinology
  • Bone Health
  • Women's Health

Background:

  • Postmenopausal osteoporosis (Type I) is a significant health concern affecting approximately 25% of women.
  • Hormonal substitution therapy is a known preventive measure for postmenopausal osteoporosis.

Purpose of the Study:

  • To outline the indications and effective dosing for estrogen-progestin prophylaxis in high-risk postmenopausal women.
  • To emphasize that osteoporosis prevention is not the sole indication for hormone substitution.

Main Methods:

  • Risk assessment for osteoporosis using bone densitometry and risk factor evaluation.
  • Review of established effective dosages for oral and transdermal estrogen-progestin therapy.

Main Results:

  • A clear indication for estrogen-progestin prophylaxis exists in women identified as high-risk for osteoporosis.
  • Minimal effective doses are established: 0.625 mg/day conjugated estrogens or 2 mg/day estradiol orally, or 50 mcg/day estradiol transdermally, supplemented with progestin.

Conclusions:

  • Hormone substitution therapy is a recommended preventive strategy for postmenopausal osteoporosis in high-risk individuals.
  • Hormone substitution has multiple indications beyond osteoporosis prevention and should be considered for postmenopausal women without contraindications.

Related Experiment Videos